BiotechTube

ENZ215 + Prolia

Phase 3Completed
1 views this week 0 watching⚡ Active
Interest: 40/100
40
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Postmenopausal Osteoporosis

Conditions

Postmenopausal Osteoporosis

Trial Timeline

Jul 4, 2022 → Jul 18, 2024

NCT ID
NCT05405725

About ENZ215 + Prolia

ENZ215 + Prolia is a phase 3 stage product being developed by Alkem Laboratories for Postmenopausal Osteoporosis. The current trial status is completed. This product is registered under clinical trial identifier NCT05405725. Target conditions include Postmenopausal Osteoporosis.

What happened to similar drugs?

20 of 20 similar drugs in Postmenopausal Osteoporosis were approved

Approved (20) Terminated (1) Active (0)
✅Teriparatide + Strontium ranelateEli LillyApproved
✅teriparatideEli LillyApproved
✅Teriparatide + RaloxifeneEli LillyApproved
✅teriparatide + aldrenodate + raloxifeneEli LillyApproved
✅teriparatide + raloxifene HCl + placeboEli LillyApproved
✅Teriparatide + Risedronate + Placebo + Calcium + Vitamin DEli LillyApproved
✅LetrozoleNovartisApproved

Hype Score Breakdown

Clinical
17
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT05405725Phase 3Completed

Competing Products

20 competing products in Postmenopausal Osteoporosis

See all competitors
ProductCompanyStageHype Score
teriparatide + teriparatide + Placebo + Calcium Supplement + Vitamin D SupplementEli LillyPhase 3
40
teriparatide 20 micrograms/day subcutaneous + salmon calcitonin 100 IU/day subcutaneousEli LillyPhase 3
40
CT-P41 + US-licensed ProliaCelltrionPhase 3
40
LetrozoleChugai PharmaceuticalPhase 2
35
Eldecalcitol soft capsulesChugai PharmaceuticalPre-clinical
22
LetrozoleChugai PharmaceuticalPhase 2
35
LetrozoleChugai PharmaceuticalPhase 2
35
menatetranone + alfacalcidolEisaiPhase 3
40
teriparatide + raloxifene + placeboEli LillyPhase 3
40
Teriparatide + Strontium ranelateEli LillyApproved
43
teriparatideEli LillyApproved
43
LY333334 + PlaceboEli LillyPhase 1
29
Teriparatide + RaloxifeneEli LillyApproved
43
teriparatide + aldrenodate + raloxifeneEli LillyApproved
43
LAE102 SC + Placebo SC + LAE102 IV + Placebo IVEli LillyPhase 1
29
BlosozumabEli LillyPhase 1
29
BlosozumabEli LillyPhase 1
21
Arzoxifene + RaloxifeneEli LillyPhase 3
40
teriparatide + raloxifene HCl + placeboEli LillyApproved
43
Raloxifene HCL + Raloxifene HCL + PlaceboEli LillyPhase 3
40